Clinical Trials List
Protocol Number232SM201
NCT Number(ClinicalTrials.gov Identfier)NCT02386553
2015-01-26 - 2025-06-02
Phase II
Terminated2
ICD-10G12.9
Spinal muscular atrophy, unspecified
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy.
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
Biogen Idec Research Ltd.
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- WANG-TSO LEE Division of Pediatrics
- WEN-CHIN WENG Division of Pediatrics
- WUH-LIANG HWU Division of Pediatrics
- 謝正宜 Division of Pediatrics
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Spinal muscular atrophy
Objectives
The primary objective of the study is to examine the efficacy of multiple doses of Nusinersen administered intrathecally in preventing or delaying the need for respiratory intervention or death in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (SMA). Secondary objectives of this study are to examine the effects of Nusinersen in infants with genetically diagnosed and presymptomatic SMA.
Test Drug
ISIS 396443
Active Ingredient
C234H323N61O128P17S17 Na17
Dosage Form
solution for injection
Dosage
2.4
Endpoints
Primary Outcome Measures :
Time to death or respiratory intervention [ Time Frame: Up to Day 2891 ]
The time will be the age of the participant at the first occurrence of either a respiratory intervention or death. Respiratory intervention is defined as invasive or noninvasive ventilation for ≥6 hours/day continuously for 7 or more days OR tracheostomy.
Secondary Outcome Measures :
Percentage of participants developing clinically manifested spinal muscular atrophy (SMA). [ Time Frame: At 13 and 24 months of age ]
Percentage of participants alive [ Time Frame: At 13 months, and 2, 3, 4, 5, 6, 7 and 8 years of age ]
Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE) [ Time Frame: At 13 and 24 months of age ]
Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria [ Time Frame: Up to Day 2891 ]
Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale [ Time Frame: Up to Day 2891 ]
Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) [ Time Frame: Up to Day 2891 ]
Change from Baseline in weight for age/length [ Time Frame: Up to Day 2891 ]
Change from Baseline in head circumference [ Time Frame: Up to Day 2891 ]
Change from Baseline in chest circumference ratio [ Time Frame: Up to Day 2891 ]
Change from Baseline in head to chest circumference ratio [ Time Frame: Up to Day 2891 ]
Change from Baseline in arm circumference ratio [ Time Frame: Up to Day 2891 ]
Incidence of adverse events (AEs) and/or serious adverse events (SAEs) [ Time Frame: Up to Day 2891 ]
Change from Baseline in clinical laboratory parameters [ Time Frame: Up to Day 2891 ]
Assessed by the following laboratory tests: Hematology: red blood cells, hemoglobin, hematocrit, platelets, white blood cells, white blood cell differential, Blood chemistry: total protein, albumin, creatinine, cystatin C, creatine phosphokinase, blood urea nitrogen, total bilirubin (direct and indirect), alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, glucose, calcium, phosphorous, chloride, sodium, potassium. Urinalysis: specific gravity, pH, protein, glucose, ketones, bilirubin, red blood cells, white blood cells, epithelial cells, bacteria, casts, crystals
Change from Baseline in electrocardiograms (ECGs) [ Time Frame: Up to Day 2891 ]
Change from Baseline in vital signs [ Time Frame: Up to Day 2891 ]
Vital sign will be assessed by: temperature, pulse rate, resting systolic and diastolic blood pressure, and respiratory rate.
Change from Baseline in neurological examinations [ Time Frame: Up to Day 2891 ]
Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations. [ Time Frame: Up to Day 2801 ]
Time to death or respiratory intervention [ Time Frame: Up to Day 2891 ]
The time will be the age of the participant at the first occurrence of either a respiratory intervention or death. Respiratory intervention is defined as invasive or noninvasive ventilation for ≥6 hours/day continuously for 7 or more days OR tracheostomy.
Secondary Outcome Measures :
Percentage of participants developing clinically manifested spinal muscular atrophy (SMA). [ Time Frame: At 13 and 24 months of age ]
Percentage of participants alive [ Time Frame: At 13 months, and 2, 3, 4, 5, 6, 7 and 8 years of age ]
Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE) [ Time Frame: At 13 and 24 months of age ]
Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria [ Time Frame: Up to Day 2891 ]
Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale [ Time Frame: Up to Day 2891 ]
Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) [ Time Frame: Up to Day 2891 ]
Change from Baseline in weight for age/length [ Time Frame: Up to Day 2891 ]
Change from Baseline in head circumference [ Time Frame: Up to Day 2891 ]
Change from Baseline in chest circumference ratio [ Time Frame: Up to Day 2891 ]
Change from Baseline in head to chest circumference ratio [ Time Frame: Up to Day 2891 ]
Change from Baseline in arm circumference ratio [ Time Frame: Up to Day 2891 ]
Incidence of adverse events (AEs) and/or serious adverse events (SAEs) [ Time Frame: Up to Day 2891 ]
Change from Baseline in clinical laboratory parameters [ Time Frame: Up to Day 2891 ]
Assessed by the following laboratory tests: Hematology: red blood cells, hemoglobin, hematocrit, platelets, white blood cells, white blood cell differential, Blood chemistry: total protein, albumin, creatinine, cystatin C, creatine phosphokinase, blood urea nitrogen, total bilirubin (direct and indirect), alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, glucose, calcium, phosphorous, chloride, sodium, potassium. Urinalysis: specific gravity, pH, protein, glucose, ketones, bilirubin, red blood cells, white blood cells, epithelial cells, bacteria, casts, crystals
Change from Baseline in electrocardiograms (ECGs) [ Time Frame: Up to Day 2891 ]
Change from Baseline in vital signs [ Time Frame: Up to Day 2891 ]
Vital sign will be assessed by: temperature, pulse rate, resting systolic and diastolic blood pressure, and respiratory rate.
Change from Baseline in neurological examinations [ Time Frame: Up to Day 2891 ]
Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations. [ Time Frame: Up to Day 2801 ]
Inclution Criteria
Key Inclusion Criteria:
• Age ≤ 6 weeks at first dose
• Genetic documentation of 5q SMA homozygous gene deletion or mutation or compound heterozygous mutation.
• Genetic documentation of 2 or 3 copies of survival motor neuron 2 (SMN2).
• Ulnar compound muscle action potential (CMAP) ≥ 1 mV at Baseline.
• Gestational age of 37 to 42 weeks for singleton births; gestational age of 34 to 42 weeks for twins.
• Meet additional study related criteria.
• Age ≤ 6 weeks at first dose
• Genetic documentation of 5q SMA homozygous gene deletion or mutation or compound heterozygous mutation.
• Genetic documentation of 2 or 3 copies of survival motor neuron 2 (SMN2).
• Ulnar compound muscle action potential (CMAP) ≥ 1 mV at Baseline.
• Gestational age of 37 to 42 weeks for singleton births; gestational age of 34 to 42 weeks for twins.
• Meet additional study related criteria.
Exclusion Criteria
Key Exclusion Criteria:
• Hypoxemia (oxygen saturation <96% awake or asleep without any supplemental oxygen or respiratory support).
• Any clinical signs or symptoms at Screening or immediately prior to the first dosing (Day 1) that are, in the opinion of the Investigator, strongly suggestive of SMA.
• Clinically significant abnormalities in hematology or clinical chemistry parameters.
• Treatment with an investigational drug given for the treatment of SMA biological agent, or device. Any history of gene therapy, prior antisense oligonucleotide (ASO) treatment, or cell transplantation.
• Meet additional study related criteria.
• Hypoxemia (oxygen saturation <96% awake or asleep without any supplemental oxygen or respiratory support).
• Any clinical signs or symptoms at Screening or immediately prior to the first dosing (Day 1) that are, in the opinion of the Investigator, strongly suggestive of SMA.
• Clinically significant abnormalities in hematology or clinical chemistry parameters.
• Treatment with an investigational drug given for the treatment of SMA biological agent, or device. Any history of gene therapy, prior antisense oligonucleotide (ASO) treatment, or cell transplantation.
• Meet additional study related criteria.
The Estimated Number of Participants
-
Taiwan
6 participants
-
Global
25 participants
